( implied in this press release due to a ...)Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes,Health

implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA may be affected by competition, unexpected new data, technical issues, clinical trials not confirming previous results or predicting future results, label expansion requests not being submitted in a timely manner or receiving regulatory approval, or manufacturing and supply issues. The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin and Lilly's most recently filed SEC documents such as their Quarterly Reports on Form 10-Q. Amylin and Lilly undertake no duty to update these forward-looking statements.

    


    P-LLY


    (1) Kendall D, Blonde L, Mac S, Guan X, Holcombe J, Okerson T, Kim D, and

        Bhole D. "Improvements in Cardiovascular Risk Factors Accompanied

        Improved Glycemic Control Weight Reduction in Patients With Type 2

        Diabetes Treated With Exenatide for 3.5 y." Abstract 0557-P.

    (2) American Heart Association. "LDL and HDL Cholesterol: What's Bad and

        What's Good?" Available at:

        http://www.americanheart.org/presenter.jhtml?identifier=180. Accessed

        June 14, 2007.

    (3) The International Diabetes Federation Diabetes Atlas. Available at:

  http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A.

        Accessed June 14, 2007.

    (4)"All About Diabetes." American Diabetes Association. Available at:

        




Page: 1 2 3 4 5 6 
Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of
Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe
Toxicities Including Heart Damage When Compared to
Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical
Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis
Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in
Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3
Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and
Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination
Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
Breast Cancer